Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has announced encouraging results from its phase I/II clinical trial, JSKN003-102, for treating advanced solid tumors, which were presented at the 2024 ASCO Annual Meeting. The study showed that JSKN003 was well-tolerated with a low occurrence of serious side effects and demonstrated a 51.1% objective response rate among heavily pretreated patients, including those with low HER2 expression and prior anti-HER2 treatments.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
